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Summary
We have examined previously the peptide specificity of the T cell response to myelin basic protein
(MBP) in patients with multiple sclerosis (MS) and healthy controls, and demonstrated that an
epitope spanning amino acids 87-106 was frequently recognized. Because this region is
encephalitogenic in some experimental animals, it has been postulated that the response to the
epitope may have relevance to MS. In this study, the fine specificity of this response is studied
using four well-characterized, monospecific T cell lines from three MS patients and an identical
twin of a patient. Each of the lines recognized a peptide with the same core sequence, amino
acids 89-99, although the responses were affected to various degrees by truncations at the 000H-
or NH2 terminal ends of the 87-106 epitope. Importantly, the epitope was recognized in
conjunction with four different HLA-DR molecules. Also, the T cell receptor /3 chain usage
was heterogeneous, and each line expressed a different VDJ sequence. The four HLADR molecules
restricting the response to this epitope have been shown to be overrepresented in MS populations
in various geographic areas, suggesting that the response to this region of the MBP molecule
may be relevant to the pathogenesis of MS. These findings may have important implications
in designing therapeutic strategies for the disease.
Although the cause of multiple sclerosis (MS)' is not
13. known, a T cell-mediated autoimmune process has been
postulated. Myelin basic protein (MBP) is a potential target
antigen because it induces experimental allergic encephalomye-
litis (EAE) in susceptible animals. Encephalitogenic epitopes
of MBP differ among susceptible strains and correlate with
the MHC class II genotype (1) . The TCRs expressed by en-
cephalitogenic T cellsfrom PL/J and B10YL mice and Lewis
rats use the same TCR V(3 chain, V08.2, and have similari-
ties in their VDJ regions, as reviewed in reference 2. Thus,
the pathogenesis of EAE is related to the capacity of T cells
with the appropriate TCRs to recognize epitopes of MBP
1 Abbreviations used in this paper. aa, amino acid; EAE, experimental allergic
encephalomyelitis; HTC, homozygous typing cells; ICAM-1, intracellular
adhesion molecule 1; MBP, myelin basic protein; MS, multiple sclerosis;
TCL, T cell line.
19
presented in conjunction with classII MHC molecules. These
requirements have provided rationales for therapeutic strate-
gies that prevent or treat EAE (3-7).
The analysis of the T cell response to MBP in patients with
MS and in healthy controls has shown that several regions
of the molecule are frequently recognized (8-10). One re-
gion, an epitope spanning amino acids (aa) 87-106, was rec-
ognized by >50% of T cell lines (TCL) derived from both
MS patients and controls (9). Our findings indicated that
several HLADR molecules couldserve as restriction elements
for MBP or fragments of the molecule. In contrast, other
investigators have reported that an epitope spanning as 84-102
is predominantly recognized by TCL from MS patients and
largely restricted by HLA-DR2 (11). To examine the fine
specificity of the T cell response to the 87-106 region ofMBP,
we have used TCL that were generated by repeated stimula-
tion with MBP until they were specific for a single region
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19-24of the molecule. Four lines specific for peptide 87-106 were
identified and selected to examine the HLA restriction, the
peptide specificity, and TCR a chain usage.
Materials and Methods
T Cell Lines andCytotoxic Assays.
￿
PBL from threepatients with
chronic progressive MS: MS1 (DR2,4; DQ1,3), MS18 (DR15,-;
DQw6,-; Dw2), and MS20 (DR4,13; DQw6w7), and the healthy
identical twin of MS20 (C8) were isolated from a leukapheresis.
MBP-specific long-term TCL were established by weekly stimula-
tion with MBP (prepared as described; 10). Each line was continu-
ously kept in culture between 8 and 16 mo. Cytotoxic activity was
tested in "Cr release assays. Briefly, 5 x 101 cells of HLA-typed
EBVtransformed B cell lines, homozygous typing cells (HTC; 10th
International Histocompatibility Workshop), or fibroblast trans-
fectants (see below) were incubated with 200 P.g/ml MBP or 100
ttg/ml peptides (solid phase method; the as sequence of all pep-
tides is based on the porcine MBP; reference 1) for 1 h before 200
p,Ci "Cr-sodiumchromate (New England Nuclear, Boston, MA)
was added for another 90 min. 100 pl of target cells (5 x 10°/ml)
was seeded in triplicates into 96-well microtiter plates (Costar, Cam-
bridge, MA) prefilled with 100 Al of effector cells (TCL) according
to desired E/T ratios. Supernatants were harvested after4 h (trans-
fectants, 5-6 h), and percent specific lysis was calculated as described
(9). The HLA class II types of HTC used as targets for the experi-
ments shown in Fig. 1 and 2 are: 9033 (DR4; DQw8; Dw4;
DP4); 9028 (DR4; DQw8; Dw14; DP4); 9053 (DR13; DQw6;
Dw19; DP4), and 9081 (DR15, DQw6; Dw2; DP4). Antibody
blocking, proliferative assays, and phenotyping were performed as
described (9).
Transfectants.
￿
Mouse L cells transfected with full-length cDNA
clones for DRa and DR2 Dw2a or DR2 Dw2b will be described
elsewhere (laraquemada et al., manuscript in preparation). 5B.6 and
3B.4 are clones of DAP.3 cells expressing DR2 Dw2a and DR2
Dw2b. The vector used for thesetransfections contained the Esche-
richia coli gpt gene, and cells were grown in medium supplemented
with 6 jug/ml mycophenolic acid (Gibco Laboratories, Grand Is-
lands, NY), 250 lAg/ml xanthine (Calbiochem-Behring Corp., La
Jolla, CA), and 15 1Ag/ml hypoxanthine (Sigma Chemical Co., St.
Louis, MO). 3B.4 and 5B.6 were retr'ansfected with the gene for
intracellular adhesion molecule 1 (ICAM-1) inserted in the vector
CDMS under the control of a cytomegalovirus promoter (12) to-
gether with the plasmid pSV2-neo for selection in 0.5 mg/ml G418
(active ingredient; Gibco Laboratories). HumanMl fibroblasts were
transfected with the full-length cDNA clone for DRa inserted
into the RSV.5 (neo)vector (Long, E. O., manuscript in prepara-
tion) together with a full-length cDNA for the DRB10401(Dw4)
gene inserted into the RSV.3 vector as described (13) . Transfected
cells were selected in 0.5 mg/ml G418 (active ingredient), and cells
expressing HLA-DR were isolated by cell sorting.
Analysis ofTCR /3 Chain Usage.
￿
Total cellular RNA was pre-
pared from 10' T line cells after stimulation with MBP and 6 d
in IIT2-containing medium. TCR,3 chain genes were amplified
using the PCR and directly sequenced (Howell, M.D., manuscript
in preparation). Briefly, RNAs were reverse transcribed and cDNAs
amplified using a human TCR CO primer (5'-GCG GCT GCT
CAG GCA GTA3') and a consensus V/3 primer (5'-TG/T T A/C/T
C/T T GGT A C/T A/C A/G A/T C A-3'), which was designed
to amplifya chain rearrangements containing virtually any of the
known human TCR Q chain genes. Amplification with these
primers produces an -500-bp double-stranded product, whichcon-
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tains one-half of the V region gene and extends through the VDJ
junction approximately one-third of the way into the C region.
This provides enough information to identify the V/3 genes present
in the rearrangements isolated. Amplified DNAs were gel purified,
base denatured, and directly sequenced with T7 polymerase (Se-
quenase; United States Biochemicals Corp., Cleveland, OH) using
a CO sequencing primer (5'-CGA CCT CGG GTG GGA ACA-
3'). In each ofthe samples, a predominant rearrangement was present
and sequenceable using this strategy. The MS20 sample was also
cloned into plasmid and six independent isolates sequenced, each
of which had a sequence identical to that obtained by directly se-
quencing the PCR product.
Results and Discussion
The fine specificity ofthe four lineswas characterized using
truncated peptides within the 87-106 sequence (Fig. 1). Pep-
tides representing either the nine NHz-terminal or 10
COOH-terminal as of this region were not recognized. Aa
90 and 96 at the NHz- and COON-terminal end, respec-
tively, are required for recognition. However, peptide 90-96
is not recognized by the lines indicating that this core se-
quence needs extension in either the NH2-terminal or the
COOH-terminal direction. Peptide 91-102, which lacks the
phenylalanine in position 90 and is extended by the tripoline
sequence at the COON terminus, is only recognized in the
context ofDR15 Dw2 by TCL MS18, indicating either minor
differences in peptide binding to this HLA-DR molecule or
influences on TCR recognition of the peptide/MHC com-
plex, or both. Similarly, for TCL C8, the NH2-terminal
histidin at position 89 is required for recognition. Support
for the potential importance of the 87-106 region comes from
the examination of the amphipathicity of the MBP mole-
cule, which has been analyzed in blocks of 11 as representing
three helical turns (13a). In the region of as 87-106, the highest
amphipathic indices (2.52-3.38) were obtained at midpoint
as at positions 88-91. An earlier study testing PBL for pri-
mary lymphoproliferative responses to human MBP and a
number of MBP peptides obtained positive responses to MBP
peptide 83-96 with PBL from MS patients, but not from
controls (14). In addition, the peptide 87-106 includes regions
encephalitogenic in experimental animals. The epitope 91-101
represents one minimal sequence encephalitogenic in SJ/L
mice (1, 2). The region 87-99 of human MBP (aa 88-100
according to the nomenclature in this study) has also been
found to be encephalitogenic in the Lewis rat (15) . The en-
cephalitogenic epitope in SJ/L mice and the region ofhuman
MBP encephalitogenic in the Lewis rat are all included in
the peptide 87-106. Minor differences in the location of the
core sequence may be due to differences in the MHC class
II elements in various species.
We next examined the restriction elements used by the four
TCL. All of the MBP-specific TCL were restricted by HLA-
DR based on antibody blocking (data not shown). Detailed
examination of restriction using HTC showed that each of
the lines was restricted by a different DR molecule (Fig. 2).
The restriction ofMS1 and MS18 was confirmed usingfibro-
blasts cotransfected with cDNAs for DRa and DR8 chains
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Figure 1 .
￿
Fine specificity of MBP-specific cytotoxic TCL MS1, MS18, MS20, and C8. Targets pulsed with MBP peptide 87-106 are lysed by each
TCL. Patients 87-96 and 89-99 represent the minimal sequences recognized. Minor differences exist for the recognition pattern of MS18 and CS and
are discussed in the text.
derived from the DR4 Dw4 (M1 DR4) and the DR15 Dw2
(DR2a; transfectant 5B.6 ICAM1) haplotypes, respectively
(Fig. 3). The inability of TCL MS20 to lyse L cells trans-
fected with DRot and DR/3 from the DR4 Dw14 (L300.7)
haplotype (kindly provided by Dr. R. Karr, University of
Iowa, Iowa City) is probably due to the absence of human
adhesion molecules on murine L cells. MS20 did proliferate
when peptide 87-106 was presented by L300.7 (data not
shown). L cells transfected with a and (3 chains from the
DR13 Dw19 haplotype were not available, however, the re-
striction of TCL C8 by HLA-DR had been established ear-
lier by antibody blocking (9). Similar observations have been
made with a malaria circumsporozoite antigen that can be
presented to T cells in the context of multiple HLA class
II antigens (16). The present report is the first known descrip-
tion ofsuch a permissive restriction for a human autoantigen.
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The restriction elements used by the TCL derived from MS
patients, DR15 (a split of DR2) and DR4, have been shown
to be overrepresented in caucasian and Arab populations of
MS patients (17). DR13 (a split of DR6), the restriction ele-
ment ofTCL C8, is associated with MS in Japanese and Mex-
ican MS patients, populations that show a low incidence of
MS (18, 19).
TCL MS20 and C8 are derived from a pair of monozygotic
HLA-DR4, DR13-positive twins discordant for MS. Both
lines recognize the 87-106 peptide, but use different restric-
tion molecules, demonstrating that the peptide can be
presented by both DR molecules. Since the expression ofthe
two DR molecules should be similar in both twins, it is likely
that the difference in the dominant reactivity is due to TCR
usage. To address this question, the TCR 0 chains used by
the four lines were studied by PCR amplification and direct
TCL C8
Figure 2.
￿
HLA restriction of TCL
MS1, MS18, MS20, and CS using HTC
pulsed with MBP peptide 87-106. MS1
is restricted by DR4 Dw4, MS18 by
DR15 Dw2, MS20 byDR4 Dw14, and
CS byDR13 Dw19. TCL C8, to alesser
DR15 Dw2
￿
extent, also recognizes the peptide in
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￿
association with DR4 Dw14, the re-
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￿
striction element used by TCL MS20
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derived from the affected twin.
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87-106 UUHF FKNIUTPRTP PPSQGK
87-95 UUHF FKNIU
87-96 UUHF FKNIUT
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91-99 FKNIUTPRT 10
91-98 FKHIUTPR
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Figure 3.
￿
TCL MS1 recognizes Ml fibroblasts transfected with DRa
and DRBI derived from the DR4 Dw4 haplotype (Ml DR4) or DR4
Dw4-positive HTC pulsed with MBP or peptide 87-106. Untransfected
Ml cells or Ml cells transfected with other DR antigens were not lysed
(data not shown). TCL MS18 recognizes MBP or peptide 87-106 when
presented on HTC in association with DR15 Dw2. L cell transfectants
expressing ICAM-1 and DR15 Dw2a (5B.6 ICAM-1) and pulsed with
MBP orpeptide87-106arealso lysed, but not those transfectants expressing
DR15 Dw2b (3B.4 ICAM-1) .
sequencing (Fig. 4). Three different V/3 families were used
with the affected and the unaffected twins, both expressing
V08. Each line used a distinctJa gene. The overall sequence
of the VDJ regions differed among the four lines. This is
in contrast with a recent report documenting a restricted usage
of V017 in the response to a similar MBP peptide (84-102)
in MS patients (20).:It is also in contrast with the common
usage of V08.2 found in encephalitogenic T cells from PL/J
and B10.PL mice and the Lewis rat (reviewed in reference
2). The different V(3 usage(Va17) in SJ/L mice (2) indicates
that TCR a chain usage or factors other than TCR are im-
portant for susceptibility. Support for this notion comes from
a recent report demonstrating a limited heterogeneity of rear-
ranged TCR Vot transcripts in the brains ofMS patients (21).
In addition, although a similar VDJ motifis found in B10.PL
mice and the Lewis rat (2, 6), differences have been reported
in T cells from PL/J mice with the same MBP specificity
(2). By analogy, a considerable heterogeneity in TCR usage
in the outbred humanpopulation is not surprising. The differ-
ences in the V0 usagein the human lines that recognize the
same peptide are consistent with the hypothesis that parts
of the TCR V region presumably bind to the third hyper-
variable region (HVR) of the DR3 chain (22). Each of the
TCL uses a different restriction element and each of the DR3
chains shows differences in the third HVR (23). These findings
suggest that individual responses to this region of the MBP
molecule will show differences with respect to HLA class
II restriction, peptide fine specificities, and TCR usage.
It is postulated that recognition of an immunogenic re-
gion ofMBP (aa 87-106), which is encephalitogenic in some
experimental animals, may be related to the pathogenesis of
MS. Support for this hypothesis comes from the observation
that this peptide can be presented by multiple HLA-DR mol-
ecules each previously associated with MS. Since the peptide
is recognizedby T cells from healthy individuals, it is likely
that the cellular response to MBP and to the 87-106 peptide
specifically is not sufficient for disease. The fact that only
one twin in this study is affected indicates that either somatic
events such as the generation of individual TCR or environ-
mental factors are responsible for the expression of disease.
In addition to the possible relationship between TCR usage
and disease other genetic or environmental factors may affect
T cell entry into the central nervous system or HLA class
II expression on brain cells. Crossreactive epitopes between
infectious agents and autoantigens also need to be consid-
ered. Although these findings require confirmation in larger
numbers ofpatients, they may have therapeutic implications.
Treatment of experimental animals with antibody to the V
regions of the TCR (7) or immunization with peptide ho-
mologous to V or J regions of the TCR (5, 6) have been
shown to modify EAE. Our results are not consistent with
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VB DB JB
MS1 Y L C A S R P G P R D T Q Y
tat ctc tgt gcc agc agg ccg gga ccg aga gat acg cag tat V36.6-J82 .3
MS18 Y L C A S S L R G A L N I Q Y
tat ctc tgt gcc agc agc ttg agg ggg gcg cta aac att cag tat VB5.2-JB2.4
MS20 Y F C A S S R K D S P S S P L H
tac ttc tgt gcc agc agc cgt aaa gac agt ccc agt tca ccc ctc cac V98-JBIA Figure 4. Nucleotide sequences
andpredicted as sequences ofTCR
C8 Y F C A S T W T N N s K L /3 chain genes from MBP-specific
tac ttc tgt gcc agc acc tgg acg aat aat gaa aaa ctg V88-JBI . 4 TCL MS1, MS18, MS20, and C8.
-f- BCLDR4MBP BCL DR15 MBP
--0- BCLDR4 87-106 ---0- BCLDR1587-106
- a- BCLDR4- -o- BCL DR15-
~r- M1 DR4MBP 58.61CAM1 MBP
-~' M1 DR487-106 58.61CAM1 87-106
M1 DR4- 58.61CAM1 -
3B.41CAM1 MBP
-O- 3B.41CAM1 87-106
3B.41CAM1 -a recent report of common V(3 usage in MBP-specific TCL
from MS patients (20), and suggest that therapies targeting
TCR regions maybe more complicated than anticipated from
experimental systems. Encephalitogenic peptides, mutated so
as to allow binding to MHC, but to eliminate T cell recog-
nition, also have been used to block induction of EAE (3,
4). Although the 87-106 peptide could be used in a similar
approach, theblockade ofDR molecules, especially with pep-
tides capableofbinding to multiple HLA-DR molecules, has
a potential for marked immuno-suppression. Nevertheless,
clinical trials using the above therapies may be important in
substantiating the role of MBP in the pathogenesis of MS.
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